A prospective, double-blind, randomized controlled trial study of the effect of immune modulation on the prognosis of sepsis

Clinical study on thymidine regulation of immune function in patients with sepsis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060069

Enrollment

Unknown

Registered

2022-05-17

Start date

2022-06-01

Completion date

Unknown

Last updated

2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Experimental group:Thymopentin

Control group:Normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Sepsis was diagnosed according to sepsis 3.0 criteria; 2. Aged >= 18 years; 3. The patient gave written consent to the study.

Exclusion criteria

Exclusion criteria: 1. In pregnancy; 2. Have a history of organ transplantation; 3. Received immunosuppressive therapy within the last three months; 4. Complicated with various tumors, hematological diseases or AIDS; 5. Terminal disease, expected survival time less than 28 days; 6. Allergy to thymosin.

Design outcomes

Primary

Measure	Time frame
28-day mortality rate;	—

Secondary

Measure	Time frame
7-day mortality rate;CD3+ T lymphocytes;CD4+ T lymphocytes;CD8+ T lymphocytes;ICU length of stay;Mechanical ventilation time;Restrictive antibiotic dosage during hospitalization;Acute Physiology and Chronic Health Status Scoring System (APACHE?) Score;Sequential Organ Failure Assessment Score (SOFA);	—

Countries

China

Contacts

Public ContactHan Yi

The First Affiliated Hospital with Nanjing Medical University

hanyi@jsph.org.cn+86 25 68305051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026